Cochrane · systematic review · CD010871
Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non‐pregnant women
Páez‐Canro, C, Alzate, JP, González, LM, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
Sexually Transmitted InfectionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
17
current version
GRADE rated
12
No studies
5
Included studies
NR
No studies 5 · 29.4%Ungraded 0 · 0%Very low 5 · 29.4%Low 5 · 29.4%Moderate 2 · 11.8%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Azithromycin compared to doxycycline for treating genital Chlamydia trachomatis infection in men and non‐pregnant women
Population: men and non‐pregnant women with symptomatic (uterine cervicitis and urethritis), or asymptomatic genital CT infection, diagnosed by cell culture or NAAT
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Microbiological failure Men Azithromycin vs doxycycline | RR 2.45 [1.36, 4.41] | 9 studies · 821 participants | Moderate Downgraded: risk of bias, imprecision |
Microbiological failure Women Azithromycin vs doxycycline | RR 1.71 [0.48, 6.16] | 5 studies · 338 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events Men Azithromycin vs doxycycline | RR 0.83 [0.67, 1.02] | 6 studies · 1424 participants | Low Downgraded: risk of bias, imprecision |
Adverse events Men and women Azithromycin vs doxycycline | RR 0.83 [0.71, 0.98] | 9 studies · 2261 participants | Moderate Downgraded: risk of bias, imprecision |
Clinical failure Men Azithromycin vs doxycycline | RR 0.94 [0.43, 2.05] | 3 studies · 525 participants | Low Downgraded: imprecision, inconsistency |
Clinical failure Women Azithromycin vs doxycycline | no estimate extracted | NR | No studies |
Antimicrobial resistance Azithromycin vs doxycycline | no estimate extracted | NR | No studies |
Reinfection Azithromycin vs doxycycline | no estimate extracted | NR | No studies |
Doxycycline compared to quinolones for treating genital Chlamydia trachomatis infection in men and non‐pregnant women
Population: men and non‐pregnant women with symptomatic (uterine cervicitis and urethritis), or asymptomatic genital CT infection, diagnosed by cell culture or NAAT for CT
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Microbiological failure Men Doxycycline 100 mg twice a day for 7 days vs ofloxacin 200 mg‐400 mg once a day for 7 days Doxycycline vs quinolones | RR 8.53 [0.43, 167.38] | 2 studies · 80 participants | Very low Downgraded: risk of bias, imprecision |
Microbiological failure Women Doxycycline 100 mg twice a day for 7 days vs ofloxacin 400 mg once a day for 7 days Doxycycline vs quinolones | no estimate extracted | 1 study · 83 participants | Low Downgraded: risk of bias, imprecision |
Microbiological failure Men and women Doxycycline 100 mg twice a day for 7 days vs ofloxacin 300 mg once a day for 7 days Doxycycline vs quinolones | no estimate extracted | 1 study · 18 participants | Low Downgraded: risk of bias, imprecision |
Adverse events Men and women Assessed by participants' self‐report Doxycycline vs quinolones | RR 1.02 [0.66, 1.55] | 3 studies · 339 participants | Very low Downgraded: risk of bias, imprecision |
Clinical failure Men Doxycycline 100 mg twice a day for 7 days vs ofloxacin 400 mg once a day for 7 days Doxycycline vs quinolones | RR 0.85 [0.28, 2.62] | 1 study · 36 participants | Very low Downgraded: risk of bias, imprecision |
Clinical failure Women Doxycycline 100 mg twice a day for 7 days vs ofloxacin 400 mg once a day for 7 days. Doxycycline vs quinolones | RR 0.94 [0.39, 2.25] | 2 studies · 127 participants | Very low Downgraded: risk of bias, imprecision |
Clinical failure Men Doxycycline 100 mg twice a day for 7 days vs ofloxacin 300 mg once a day for 7 days Doxycycline vs quinolones | no estimate extracted | 1 study · 18 participants | Low Downgraded: risk of bias, imprecision |
Antimicrobial resistance Doxycycline vs quinolones | no estimate extracted | NR | No studies |
Reinfection Doxycycline vs quinolones | no estimate extracted | NR | No studies |